Biomarin Pharmaceutical Inc (BMRN)
Healthcare
Biotechnology
60.00 $
+0.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Biomarin Pharmaceutical Inc (BMRN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 102.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
102.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
99.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
193Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 10.25 | 19,818,301 | +3.6 | 03/31/2026 |
| Dodge & Cox | 7.53 | 14,561,759 | -0.1 | 03/31/2026 |
| PRIMECAP Management Company | 7.34 | 14,194,005 | -2.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.47 | 8,643,164 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.29 | 8,298,475 | +0.0 | 03/31/2026 |
| AQR Capital Management LLC | 3.97 | 7,676,541 | +14.8 | 03/31/2026 |
| State Street Corp | 3.77 | 7,295,079 | -3.0 | 03/31/2026 |
| Viking Global Investors LP | 3.65 | 7,062,077 | +17.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Dodge & Cox Stock I | 5.05 | 9,769,625 | +0.0 | 06/30/2026 |
| iShares Core S&P Mid-Cap ETF | 3.43 | 6,638,585 | +0.0 | 07/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.